Obstructive Sleep Apnea
Conditions
Keywords
Biomarkers, Genomics
Brief summary
Potential biomarkers for obstructive sleep apnea (OSA), and full genomic screening will be evaluated and correlated to the degree of OSA and to effect of CPAP-treatment measured by polygraphy.
Detailed description
This project includes two parts: * Genomic screening * Biomarkers
Interventions
None listed
Sponsors
Karolinska University Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
OSA-patients with moderate and severe OSA (n=15+15) 1. Adult, 18-75 years of age 2. Moderate (AHI 15-30) or Severe (AHI \>30) OSA that are currently untreated and planned for CPAP-treatment 3. Otherwise healthy except for well controlled hypertension since 3 month, Max BP 140/90 4. Non-smokers 5. Not pregnant 6. No medications with antioxidants 7. BMI of \<40 Controls (AHI\<5) Two groups of controls 1. Matched controls The same age, sex and BMI ± 3 and eventual hypertension. These controls should also fulfill criteria 4-6 above. 2. Healthy controls with normal BMI (19-25) These controls should also fulfill criteria 1., 4-6 above.
Exclusion criteria
* If they no not fulfil the inclusion criteria
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Biomarker | Comparison between 0, 3 and 12 month | Biomarkers related to inflammation, hypoxia, oxidative stress, redox and the central nervous system will be measured |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Genomics | Comparison between 0, 3, 12 month | Genomic screening by microarray |
| Apnea hypopnea index | Comparision between 0, 3 and 12 month | Apnea hypopnea index at 0, 3 and 12 month after treatment with CPAP in the obstructive sleep apnea groups |
| Exhaled nitric oxide | Comparision at 0, 3 and 12 month | Measurement of exhaled nitric oxide |
Countries
Sweden
Outcome results
None listed